STK11, KEAP as Targets, What Are They, and Should Results Enter Into Clinical Decision Making

dbrock's picture
ASCO 2019 LC RoundTable - STK11 and KEAP as Targets, What Are They, and Should Results Enter Into Clinical Decision Making
H. Jack West, MD, Founder, President and CEO

We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services at City of Hope Comprehensive Cancer Center, and Founder, President and CEO Of GRACE, Charu Aggarwal, MD, MPH with the Perelman Center for Advanced Medicine, University of Pennsylvania, and Benjamin Levy MD, Clinical Director Of Medical Oncology, Assistant Professor Of Oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital.

The doctors recently collaborated from their respective geographical locations to review top discussion points from Lung Cancer from ASCO 2019.  In this video, the doctors discuss their thoughts on STK11 and KEAP as targets, what are they and whether the results should enter into clinical decision making.  

Please visit our community forums with any questions or comments! 

 

 

Video Language: 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation